论文部分内容阅读
二次探查术(简称二探)是作为估价卵巢上皮性癌化疗效果的一种手术。尽管已普遍接受,但对预后的意义尚难定论。二探阴性通常被认为是无瘤,视为治愈。不过有几篇报道曾提到二探阴性以后再复发,其发生率为13%～50%。为探寻其复发的因素,分析24例二探阴性患者。其中4例(17%)以后又有复发。二探后复发时间为11～36个月。4例复发者皆为晚期及组织学Ⅲ级肿瘤。2例在初次手术时残存肿瘤直径超过1 cm。而在早期的患者(Ⅰ或Ⅱ期)无论其组织学分级如何,皆无复发。4例初次手术残存肿瘤直径大于1 cm者也仅2例发生组织Ⅲ级的复发。
Secondary exploration (referred to as the second probe) is used as a valuation of epithelial ovarian cancer chemotherapy effect of a surgery. Although generally accepted, the significance of prognosis is inconclusive. Negative biopsy is generally considered tumor-free and considered as cure. However, there are several reports that mentioned two negative recurrence after the test, the incidence was 13% to 50%. In order to find out the factors of recurrence, 24 cases with negative second test were analyzed. Four of them (17%) had recurrence later. Second exploration after the recurrence time is 11 to 36 months. Four cases of recurrence were advanced and histological grade Ⅲ tumors. In 2 cases, residual tumor diameter exceeded 1 cm at the time of initial operation. In the early stage of patients (stage I or II), there was no recurrence regardless of histological grade. In 4 cases with surgically resected tumors more than 1 cm in diameter, there were only 2 cases of tissue grade Ⅲ recurrence.